title: Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
abstract: Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
authors.affiliation: Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle, UK. Electronic address: k.c.p.wu@ncl.ac.uk.
authors.forename: Keith C P
authors.initials: KCP
authors.lastname: Wu
authors.affiliation: Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle, UK.
authors.forename: Zarif K
authors.initials: ZK
authors.lastname: Jabbar-Lopez
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D000069444:Omalizumab; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D006634:Histamine H1 Antagonists; D000069444:Omalizumab